DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis


Nolan B, Mahlangu J, Young G. et al.
ASPIRE final results confirm established safety and sustained efficacy for up to 4 years of treatment with rFVIIIFc in previously treated subjects with severe hemophilia A.

Blood 2018;
132 (Supplement 1): 1192

Download Bibliographical Data

Search in: